MP
CGON icon

Mangrove Partners’s CG Oncology CGON Stock Holding History

Mangrove Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-671,692
Closed -$27.1M – 392
2025
Q3 		$27.1M Buy
671,692
+116,575
+21% +$3.39M 2% 20
2025
Q2 		$14.4M Buy
+555,117
New +$13.4M 1.55% 23

Other funds holding CGON

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Mangrove Partners's CGON Position: Q4 2025 in Review

Mangrove Partners sold out of CG Oncology (CGON) in Q4 2025, closing a stake of 671,692 shares — an estimated $27.1M sold.

Mangrove Partners first reported a position in CGON in Q2 2025 and held it in 2 quarters. The position peaked at $27.1M in Q3 2025. 195 funds tracked by Wall St. Rank hold CGON as of Q4 2025.

  • Mangrove Partners reported no remaining CG Oncology position as of Q4 2025 after selling out during the quarter.
  • Mangrove Partners sold 671,692 CG Oncology shares in Q4 2025, an estimated $27.1M.
  • Mangrove Partners first reported a position in CG Oncology in Q2 2025 and held it in 2 quarters.
  • Mangrove Partners's CG Oncology position peaked at $27.1M in Q3 2025.
  • 195 funds tracked by Wall St. Rank held CG Oncology as of Q4 2025.

Based on Mangrove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.